Physician profile
Tin Bui
NPI 1356846265
$2,461.41
in general payments reported to CMS, 2019-2025
21 companies · $199 in 2025
The $199 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $129 · 2021: $819 · 2022: $139 · 2023: $395 · 2024: $655 · 2025: $199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,248.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $567.74 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Biohaven Pharmaceuticals, INC. | $275.15 | 2021 | |
| Janssen Pharmaceuticals, INC | $274.95 | 2021 | |
| Abbvie INC. | $228.76 | 2020-2024 | Vraylar |
| Glaxosmithkline, LLC. | $170.54 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $128.34 | 2023-2025 | Ozempic, Rybelsus |
| Paratek Pharmaceuticals, INC. | $123.97 | 2021 | |
| Neurocrine Biosciences, INC. | $110.87 | 2020 | |
| Pfizer INC. | $88.15 | 2023-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.90 | 2023-2025 | Xifaxan |
| Astellas Pharma US INC | $60.96 | 2024-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $60.54 | 2024 | |
| Dexcom, INC. | $53.50 | 2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $50.11 | 2024-2025 | Mounjaro |
| Exact Sciences Corporation | $48.48 | 2024-2025 | Cologuard Collection Kit |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $36.07 | 2024-2025 | Repatha, Otezla, Repatha |
| Intra-Sana Laboratories | $34.79 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.18 | 2025 | Jardiance |
| Medtronic, INC. | $24.44 | 2024 | Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $18.33 | 2023 | Steglujan, Steglatro, Belsomra |
| Epi Health, LLC | $16.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tin Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.